Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug gets your gut moving faster after bowel surgery?

NCT ID NCT06112353

Symptom relief Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study compares two medications used to reverse muscle relaxants after bowel surgery: Sugammadex versus Neostigmine with Glycopyrrolate. The goal is to see which one helps patients have their first bowel movement and tolerate solid food sooner. About 128 adults undergoing laparoscopic bowel resection will be randomly assigned to one of the two drugs, and researchers will track recovery time, hospital stay length, and costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sugammadex injection and Neostigmine Injectable Solution (with Glycopyrrolate)
What this could lead to
If it works, this could help patients recover bowel function faster after surgery, potentially shortening hospital stays and reducing costs.
What could go wrong
This is a small, early-phase trial (128 participants) comparing two existing drugs, so any benefit may be modest or not apply to all patients. Risks include side effects like slowed heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

132 people

The number who actually took part.

Started

Apr 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or older * Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission Exclusion Criteria: * Allergy to Rocuronium, Vecuronium, or Sugammadex * Bowel resection surgery requiring an ostomy * No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality * No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin * Creatinine Clearance (CrCl) of less than 30 * Pregnancy * Incapable of providing consent or understanding the research project

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intestinal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intestinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intestinal disease

Contacts and locations

Locations

  • UC Irvine Medical Center

    Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.